Management of factor VIII inhibitors

International Journal of Hematology

Volumn 83, Issue 2, 2006, Pages 119-125

  DiMichele, Donna M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b New York Weill Cornell Center   (United States)

Author keywords

Hemophilia A; Immune tolerance; Inhibitors; Prothrombin complex concentrates; Recombinant factor VIIA

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; BLEEDING; BLOOD CLOTTING; DRUG MECHANISM; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; PLASMAPHERESIS; REVIEW; DISEASE MANAGEMENT; IMMUNOLOGY;

DISEASE MANAGEMENT; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE;

EID: 33646830665     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05129     Document Type: Review

References (79)

1. DiMichele DM, Neufeld EJ. Hemophilia: a new approach to an old disease. Hematol Oncol Clin North Am. 1998;12:1315-1344.
2. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica. 2000;85:7-13.
3. Peerlinck K, Jacquemin M. Characterization of inhibitors in congenital hemophilia. In: Rodriguez-Merchan EC, Lee CA, eds. Inhibitors in Patients with Haemophilia. Oxford, UK: Blackwell; 2002:9-13.
4. Lacroix-Desmazes S, Sooryanarayana, Moreau A, Kazatchkine MD, Kaveri SV. Factor VIII inhibitor with catalytic activity towards factor VIII. Haematologica. 2000;85(suppl):89-92.
5. Arai M, Scandella D, Hover LW. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest. 1989;83:1978-1984.
6. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240-246.
7. Kazatchkine MD, Sultan Y, Burton-Kee EJ, Mowbray JF. Circulating immune complexes containing anti-FVIII antibodies in multitransfused patients with hemophilia A. Clin Exp Immunol. 1980;39:315-320.
8. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594-598.
9. Brown DL, Bray GL, Scharrer I. Transient inhibitors in patients with hemophilia A [abstract]. Thromb Haemost. 1999;82(suppl):573. Abstract 1804.
10. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated individuals with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428-2435.
11. Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BBD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost. 1999;82:1493.
12. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19:139-148.
13. Kreuz W, Ettingshausen CE, Auerswald G, et al, for the GTH PUP Study Group. Epidemiology of inhibitors and current treatment strategies. Haematologica. 2003;88:EREP04.
14. Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh. 1975;34:612.
15. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247-251.
16. Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in hemophilia A: introduction and systematic review of current practice. Haemophilia. 2003;9:405-417.
17. White GC 2nd, Rosendaal F, Aledort L, Lusher JM, Rothschild C, Ingerslev J, for the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Thromb Haemost. 2001;85:560.
18. Fulcher CA. Immunochemistry of factor VIII:C inhibitor antibodies. Am J Med. 1991;91:6S-8S.
19. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993;82:2452-2461.
20. Saenko EL, Ananyeva NM, Kouiavskaia DV, et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia. 2002;8:1-11.
21. Fulcher CA, De Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A. 1985;82:7728-7732.
22. Jacquemin MG, Saint-Remy JM. Factor VIII alloantibodies in hemophilia. Curr Opin Hematol. 2004;11:146-150.
23. Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285-290.
24. Oldenberg J, Tuddenham E. Genetic basis of inhibitor development in severe hemophilia A and B. In: Rodriguez-Merchan EC, Lee CA, eds. Inhibitors in Patients with Haemophilia. Oxford, UK: Blackwell; 2002:21-26.
25. Astermark J, Berntorp E, White GC, Kroner BL, for the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267-272.
26. Addiego JR Jr, Kasper C, Abildgaard C, et al. Increased frequency of inhibitors in African American hemophilia A patients [abstract]. Blood. 1994;84(suppl 1):239a.
27. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe hemophilia: the importance of patient age. Br J Haematol. 2001;113:600-603.
28. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost. 2003;1:1228-1236.
29. Knobel KE, Sjorin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr. 2002;91:910-914.
30. Rothschild C, Goudemand J, Demiguel V, Lambert T, Calvez T. Effect of type of treatment (recombinant vs. plasmatic) on FVIII inhibitor incidence according to known risk cofactors in previously untreated severe hemophilia A patients (PUPs) [abstract]. J Thromb Haemost. 2003;1(suppl). Abstract OC215.
31. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a hemophilia A mouse model. Thromb Haemost. 2002;88:221-229.
32. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX: Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66:384-386.
33. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995;86:983-988.
34. Schulman S. Continuous infusion. Haemophilia. 2003;9:368-375.
35. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983;62:1135-1138.
36. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
37. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost. 1997;77:1113-1119.
38. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia. 2003;9:261-268.
39. Brackmann HH, Oldenberg J, Schwaab R. Immune tolerance for the treatment of FVIII inhibitors: twenty years of the Bonn protocol. Vox Sang. 1996;70(suppl 1):30-35.
40. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38:6-9.
41. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175-179.
42. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis. 1996;26(suppl 1):135-138.
43. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors: rFVIIa Study Group. Haemophilia. 1998;4:790-798.
44. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in hemophiliacs with inhibitors. Thromb Haemost. 1998;80:912-918.
45. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S45-S49.
46. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773-778.
47. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Hemostasis. 1996;26:118-123.
48. Schulman S, d'Oiron R, Martinowitz U, et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S97-S101.
49. Shapiro A. Inhibitor treatment: state of the art. Semin Hematol. 2001;38:26-34.
50. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (Novo-Seven). J Thromb Haemost. 2003;1:450-455.
51. Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38(suppl 12):6-9.
52. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83-90.
53. Ludlam CA. The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb. 2002:32(suppl 1):13-18.
54. Antovic J, Schulman S, Eelde A, Blomback M. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia. 2001;7:557-560.
55. Mariani G, Kroner B, and the Immune Tolerance Study Group (ITSG). Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica. 2001;86:1186-1193.
56. Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol. 2001;112:91-97.
57. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet. 1977;2:933,
58. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost. 2003;29:69-76.
59. DiMichele D, Kroner B, and the Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Haematologica. 2000;85(suppl):42-44.
60. Mariani G, Scheibel E, Nogao T, et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia: the International Registry of Immunetolerance Protocols. Semin Hematol. 1994;31:62-64.
61. Lenk H, and the ITT Study Group. The German Registry of immune tolerance treatment in hemophilia: 1999 update. Haematologica. 2000;85(suppl):45-47.
62. DiMichele DM, Kroner B, and the North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87:52-57.
63. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia. 1998;4:568-573.
64. Kroner BL. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang. 1999;77(suppl 1):33-37.
65. Ljung R. Central venous lines in haemophilia. Haemophilia. 2003;9(suppl 1):88-93.
66. Hay CR, Ludlam CA, Colvin BT, et al. FVIII inhibitors in mild and moderate-severity haemophilia A: UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998;79:762-766.
67. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia. 1999;5:32-39.
68. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424-4428.
69. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol. 2004;125:366-368.
70. Barrow RT, Healey JF, Gailani D, et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood. 2000;95:564-568.
71. Villard S, Lacroix-Desmazes S, Kieber-Emmons T, et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood. 2003;102:949-952.
72. + T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost. 2003;1:1777-1784.
73. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A. 1998;95:5734-5739.
74. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia: Malmö protocol update. Haematologica. 2000;85(suppl):48-51.
75. Freiburghaus C, Berntorp E, Eckman M, et al. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia. 1999;5:32-39.
76. Smith MP, Spence KJ, Waters EL, et al. Immune tolerance therapy for hemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost. 1999;81:35-38.
77. Rocino A, Papa ML, Salerno E, et al. Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: experiecne at a single institution. Hemophilia. 2001;7:33-38.
78. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, et al. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost. 1994;71:703-706.
79. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol. 1992;14:82-87.